Condition

Prostate Cancer (Adenocarcinoma) clinical trials and research

• 38Clinical trials
• 20Countries

Newest Prostate Cancer (Adenocarcinoma) clinical trials

All recruiting trials (38)

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Predicting prostate cancer response to neoadjuvant darolutamide with a gene biomarker

  This study tests whether a gene-based PCAI ImmunoScore can predict which high-risk localized or locally advanced prostate cancer patients will have minimal residual disease after 90–120 days of darolutamide before surgery.

  Recruiting at 2 sites Phase 2 Region Stockholm · Gothenburg and 1 other locations · NCT07617272

• Personal preferences for avoiding gynecomastia (Stage 1)

  This project will ask men with prostate cancer and high-risk biochemical recurrence what trade-offs they'd make to avoid breast-related side effects like gynecomastia.

  Recruiting St Vincent's Hospital, Sydney · Sydney, New South Wales · NCT07552922

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

• Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

  This project collects medical and treatment information to see how prostate cancer is diagnosed and managed in Algerian men with confirmed disease.

  Recruiting at 21 sites Société Algérienne de Formation et Recherche en Oncologie · Adrar, Algeria and 23 other locations · NCT07484971

• Whole-gland prostate dose boost versus SBRT alone for PSMA-staged localized and locally advanced prostate cancer

  We will test whether adding a whole-gland radiation boost (with brachytherapy or a stereotactic boost) improves cancer control compared with SBRT alone in men whose prostate cancer is confined to the prostate on PSMA PET.

  Recruiting Phase 2/3 Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07426055

• Ablative radiation with a focal boost for unfavorable prostate tumors

  This trial will test whether a single high-dose focal radiation or a five-fraction SBRT schedule is safe and tolerable for men with intermediate-unfavorable or selected high-risk localized prostate cancer.

  Recruiting University of Milano Bicocca · Monza, MB · NCT07407608

• Two-fraction MR-guided prostate radiation with lower dose to healthy prostate and a boost to MRI-visible tumor

  This will test whether giving two MRI-guided radiation sessions that lower dose to normal prostate tissue but keep a high dose to MRI-visible tumors reduces urinary and bowel side effects in men with low- or favorable-intermediate risk prostate cancer.

  Recruiting The Netherlands Cancer Institute · Amsterdam · NCT07391982

• Lutetium-177 dosimetry to predict response to PSMA radioligand therapy in metastatic prostate cancer

  This project will test whether measuring the radiation dose delivered (dosimetry) from Lutetium-177 PSMA therapy can predict which men with metastatic prostate cancer will respond.

  Recruiting Jules Bordet Institute · Brussels · NCT07370597

• GRPR PET imaging for diagnosis and staging of prostate cancer

  This will test two new GRPR PET tracers (68Ga-G21 and 68Ga-G23) alongside 68Ga-PSMA-11 to see if they better detect and stage prostate cancer in men with confirmed disease.

  Recruiting Phase 1/2 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07363382

• Adaptive targeted stereotactic radiotherapy for localized prostate cancer

  This tests whether doing a quick low-dose CT scan before each SBRT session to adapt the treatment plan reduces radiation to the bladder and rectum and preserves quality of life for men aged 60 and older with low- or intermediate-risk localized prostate cancer.

  Recruiting Clinique Sainte Clotilde · Saint-Denis · NCT07344844

• Micro‑ultrasound guided focal laser treatment for intermediate‑risk prostate cancer

  This will see if micro‑ultrasound–guided focal laser ablation can safely treat men with intermediate‑risk prostate cancer and delay or avoid surgery or radiation.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07339943

• Biomarker testing in men with localized prostate cancer treated with aglatimagene besadenovec

  This study will test whether giving intraprostatic aglatimagene besadenovec with oral valacyclovir alongside radiation is safe and how the viral material and immune signals behave in men with intermediate‑risk localized prostate cancer.

  Recruiting at 7 sites Phase 2 Candel Therapeutics, Inc. · Peoria, Arizona and 6 other locations · NCT07332000

• Docetaxel plus 177Lu-PSMA-I&T in first-line mCRPC

  This early-phase study tests if giving docetaxel with a fixed dose of 177Lu-PSMA-I&T is safe and tolerable for men with metastatic castration-resistant prostate cancer who have not yet had chemotherapy for this stage.

  Recruiting Phase 1 Instituto do Cancer do Estado de São Paulo · São Paulo · NCT07316686

• Relugolix with SBRT for erectile function recovery after prostate cancer therapy

  This study tests whether men with advanced prostate cancer who stop hormone therapy and receive targeted SBRT can regain erectile function within six months.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT07302451

• 68Ga-PSMA-11 PET versus mpMRI for diagnosing prostate cancer

  This test will see if 68Ga-PSMA-11 PET scans (PET/CT or PET/MRI) find prostate cancer more accurately than multiparametric MRI in men with newly diagnosed, untreated prostate cancer.

  Recruiting Phase 2/3 First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07209878

• Dyadic co-learning program for men with prostate cancer and their spouses

  This program will test whether an 8-week co-learning course with weekly topics, a mobile app, and professional support helps men with prostate cancer and their cohabiting spouses feel better physically and emotionally and become more resilient.

  Recruiting National Taipei University of Nursing and Health Sciences · Keelung and 1 other locations · NCT07196488

• High-dose brachytherapy before robotic radical prostatectomy for high-risk prostate cancer

  This trial will test whether a single high-dose (15 Gy) brachytherapy treatment given 4–8 weeks before robotic prostate removal helps people with newly diagnosed, non-metastatic high-risk prostate cancer.

  Recruiting Phase 1/2 The Methodist Hospital Research Institute · Houston, Texas · NCT07182279

• Sacituzumab tirumotecan plus tagitanlimab for aggressive and neuroendocrine prostate cancer

  This trial tests whether combining sacituzumab tirumotecan with the immunotherapy tagitanlimab helps people with aggressive variant or neuroendocrine prostate cancer that has progressed after newer hormonal treatments.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07179783

• PSMA PET-based 3D mixed-reality navigation for pelvic lymph node removal in prostate cancer

  The trial will try using a 3D mixed-reality model made from preoperative PSMA PET scans to guide surgeons and inform patients during robot-assisted pelvic lymph node surgery for men with prostate cancer who have up to three PSMA-positive pelvic lymph nodes.

  Recruiting Martini-Klinik am UKE GmbH · Hamburg, Free and Hanseatic City of Hamburg and 1 other locations · NCT07129551

• Using PSMA PET with MRI to watch for prostate cancer returning after focal therapy

  We will try adding a PSMA PET scan to routine MRI follow-up to see if it finds prostate cancer coming back sooner in men who had focal (partial gland) therapy.

  Recruiting University of Chicago · Chicago, Illinois · NCT07115914

• Personalized external beam radiation for localised breast and prostate tumours

  This project will test whether using optimized MRI scans plus lab-grown tumor samples can help personalize external beam radiation for adults with localized breast or prostate cancer.

  Recruiting European Institute of Oncology · Milan, Italy · NCT07047495

• Targeted radiotherapy to up to three growing prostate cancer spots in castration‑resistant disease

  This trial will try adding targeted radiotherapy to up to three progressing spots to see if it can delay the next systemic treatment and extend disease control in men with oligoprogressive castration‑resistant prostate cancer.

  Recruiting Phase 2 University Medical Center Groningen · Groningen and 1 other locations · NCT07038304

• Fezolinetant to reduce hot flashes in men on androgen-deprivation therapy

  This trial will test whether taking fezolinetant once daily for 4 weeks reduces how often and how severe hot flashes are in men with prostate cancer who are on androgen-deprivation therapy.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT06957691

• Evaluation of a new robotic surgical system for major gastrointestinal and urologic surgeries

  This study is testing a new robotic surgery system to see if it can safely and effectively help patients with major gastrointestinal and urologic conditions like colorectal and prostate cancer.

  Recruiting Chinese University of Hong Kong · Hong Kong · NCT06926374

• Robotic Prostatectomy Pain Reduction with Two Insufflation Devices

  This trial tests whether two different pneumoperitoneum devices used during robotic prostatectomy affect pain after surgery in men with prostate cancer.

  Recruiting East and North Hertfordshire NHS Trust · Stevenage, Hertfordshire · NCT06915909

• Flotufolastat F 18 PET scanning for men with very low PSA after prostatectomy

  This study will test whether a single flotufolastat F 18 PET scan can find sites of recurrent prostate cancer in men with very low PSA levels after radical prostatectomy.

  Recruiting at 2 sites Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06862856

• Talazoparib with or without enzalutamide for people with HRR-mutant mCRPC after abiraterone

  This will see if adding enzalutamide to talazoparib, or using talazoparib alone, can slow cancer progression in people with HRR-mutant metastatic castration-resistant prostate cancer who have already taken abiraterone.

  Recruiting at 8 sites Phase 2 Prostate Cancer Clinical Trials Consortium · Duarte, California and 7 other locations · NCT06844383

• Adaptive radiotherapy for localized prostate cancer

  This study is testing a new type of radiation therapy for men with localized prostate cancer who have urinary problems to see if it can safely treat their cancer without causing too many side effects.

  Recruiting University of Zurich · Heidelberg, Baden-Wurttemberg and 2 other locations · NCT06834152

• Using ARISTA polysaccharide to reduce blood loss during prostate cancer surgery

  This study is testing if using a special gel during prostate cancer surgery can help reduce blood loss and improve recovery for men having nerve-sparing surgery.

  Recruiting at 3 sites St. Antonius Hospital Gronau · Hamburg, Free and Hanseatic City of Hamburg and 2 other locations · NCT06822036

• Using PSMA-1007 Imaging for Staging Prostate Cancer

  This study is testing a new imaging method called PSMA-1007 to see if it can better detect prostate cancer and its spread to lymph nodes compared to standard imaging techniques.

  Recruiting Heinrich-Heine University, Duesseldorf · Düsseldorf, North Rhine-Westphalia · NCT06820333

• Testing ACE-232 for advanced prostate cancer treatment

  This study is testing a new treatment called ACE-232 to see if it is safe and effective for people with advanced prostate cancer that has not responded to other therapies.

  Recruiting at 8 sites Phase 1 Acerand Therapeutics Limited · La Jolla, California and 12 other locations · NCT06801236

• Reducing safety margins in stereotactic radiotherapy for prostate cancer

  This study is testing if reducing safety margins in radiation therapy for low- and medium-risk prostate cancer can make treatment safer and more effective for patients.

  Recruiting University Hospital Ostrava · Ostrava, Moravian-Silesian Region · NCT06665932

• FK-PC101 vaccine for men with high-risk prostate cancer after surgery

  This study is testing a new vaccine for men with high-risk prostate cancer after surgery to see if it can help prevent the cancer from coming back.

  Recruiting at 2 sites Phase 2 Cellvax Therapeutics Inc · Chicago, Illinois and 2 other locations · NCT06636682

• Targeting gut bacteria to improve prostate cancer treatment

  This study is testing if adding a gut bacteria-targeting medication to standard prostate cancer treatment can help men with advanced prostate cancer respond better to their therapy.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06616597

• Adding docetaxel to hormone and androgen-blocking therapy for men with metastatic prostate cancer who have a weak PSA response

  This trial tests whether adding docetaxel to standard hormone and androgen-blocking therapy helps men with metastatic, castration-sensitive prostate cancer who still have a higher-than-expected PSA after 6–12 months of treatment.

  Recruiting at 380 sites Phase 3 Canadian Cancer Trials Group · Anchorage, Alaska and 394 other locations · NCT06592924

Related topics

Quick answers

How many Prostate Cancer (Adenocarcinoma) clinical trials are recruiting right now?

38, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 20 countries. The most sites are in United States (11 trials), China (6 trials), Germany (4 trials), Italy (3 trials), Canada (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 10, Phase 2/3: 2, Phase 1/2: 2, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →